SCHEMBL2671105

SCHEMBL2671105

COC(=O)c1ccc2[nH]nc(O)c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 2/20 0.52
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
HSD17B10 Q99714 2/20 0.51
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
STAT3 P40763 1/20 0.49
HIF1A Q16665 1/20 0.49
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA7 P43166 2/20 0.49
CA9 Q16790 2/20 0.49
CA14 Q9ULX7 2/20 0.49
XDH P47989 1/20 0.49
FLT3 P36888 1/20 0.48
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
KIF11 P52732 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2671565 0.88 MAP2K4 (0.59) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL16929779 0.84 JAK2 (0.58) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1501529 0.84 KDM4E (0.55) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2569247 0.83 KDM4E (0.50) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL29301471 0.83 KDM4E (0.50) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL23675227 0.83 MAP2K4 (0.54) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL29564826 0.83 MAP2K4 (0.54) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL9985941 0.83 KDM4E (0.54) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24422909 0.83 MAP2K4 (0.54) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30159599 0.83 KDM4E (0.50) MAP2K4KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2952514-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS Pfizer Inc (US) 2015-12-09 EP disclosed
US-9181252-B2 N1/N2-lactam acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2015-11-10 US disclosed
US-9181252-B2 N1/N2-lactam acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2015-11-10 US disclosed
US-20150152109-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2015-06-04 US disclosed
US-20150152109-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2015-06-04 US disclosed
EP-2632925-B1 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER (US) 2015-05-27 EP disclosed
EP-2632925-B1 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER (US) 2015-05-27 EP disclosed
US-8993586-B2 N1/N2-lactam acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2015-03-31 US disclosed
US-8993586-B2 N1/N2-lactam acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2015-03-31 US disclosed
US-20150025098-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2015-01-22 US disclosed
US-20150025098-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2015-01-22 US disclosed
US-8859773-B2 N1/N2-lactam acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2014-10-14 US disclosed
US-8859773-B2 N1/N2-lactam acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2014-10-14 US disclosed
EP-2632925-A1 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS Pfizer Inc (US) 2013-09-04 EP disclosed
US-20120108619-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC 2012-05-03 US disclosed
US-20120108619-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC 2012-05-03 US disclosed
WO-2012056372-A1 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2012-05-03 WO disclosed
WO-2012056372-A1 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2012-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025098-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS ACACA, ACACB, COASY MAP2K4 4480/4885KDM4E 2570/4885ALDH1A1 158/4885
US-20150152109-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS ACACA, ACACB, COASY MAP2K4 4480/4885KDM4E 2570/4885ALDH1A1 158/4885
US-20120108619-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS ACACA, ACACB, COASY MAP2K4 4480/4885KDM4E 2570/4885ALDH1A1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.